Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30329317 | 0.78 | HCRTR2 (0.44) | EGLN1 | |
| SCHEMBL25164791 | 0.78 | HCRTR2 (0.44) | EGLN1 | |
| SCHEMBL30328538 | 0.76 | HCRTR2 (0.41) | EGLN1EPHX2RBP4HSD11B1GAA | |
| SCHEMBL25164543 | 0.76 | HCRTR2 (0.41) | EGLN1EPHX2RBP4HSD11B1GAA | |
| Hydrochloric Acid SCHEMBL30329400 | 0.74 | EPHX2 (0.55) | EGLN1EPHX2RBP4HSD11B1GAA | |
| SCHEMBL30327732 | 0.68 | TRPV1 (0.48) | EGLN1HSD11B1GAATRPV1 | |
| SCHEMBL25164431 | 0.66 | PTPN11 (0.43) | — | |
| SCHEMBL30328218 | 0.66 | PTPN11 (0.43) | — | |
| SCHEMBL4721522 | 0.65 | HSD11B1 (0.49) | EPHX2RBP4HSD11B1GAATRPV1 | |
| SCHEMBL30328069 | 0.65 | LIPE (0.37) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | EGLN1 2437/4885EPHX2 2639/4885RBP4 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.